32.48

3.79% 1.185

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $32.48, with a volume of 1.03M. It is up +3.79% in the last 24 hours and up +44.06% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Previous Close:

$31.30

Open:

$31.3

24h Volume:

1.03M

Relative Volume:

0.78

Market Cap:

$3.10B

Revenue:

$305.00K

Net Income/Loss:

$-328.98M

P/E Ratio:

-7.6163

EPS:

-4.2652

Net Cash Flow:

$-309.60M

1W Performance:

+2.41%

1M Performance:

+44.06%

6M Performance:

+129.58%

1Y Performance:

+62.75%

1-Day Range:

$30.91

$33.34

1-Week Range:

$30.22

$33.34

52-Week Range:

$9.90

$33.34

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

143

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	32.48	2.99B	305.00K	-328.98M	-309.60M	-4.2652
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Dec 04, 2025

Why Viridian Therapeutics Inc. (1S1) stock fits value portfolios2025 AllTime Highs & Smart Allocation Stock Tips - Newser

Dec 04, 2025

Viridian Therapeutics stock hits 52-week high at 32.58 USD - Investing.com

Dec 04, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025

How Viridian Therapeutics Inc. (1S1) stock gains from tech spendingMarket Sentiment Summary & Daily Chart Pattern Signal Reports - Newser

Dec 04, 2025

Can Viridian Therapeutics Inc. (1S1) stock retain market dominanceJuly 2025 Breakouts & Safe Entry Point Identification - Newser

Dec 04, 2025

How analysts revise price targets for Viridian Therapeutics Inc. (1S1) stockJuly 2025 Final Week & High Yield Stock Recommendations - Newser

Dec 04, 2025

Is Viridian Therapeutics Inc. (1S1) stock suitable for passive index fundsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - Newser

Dec 04, 2025

Dec 03, 2025

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Benzinga

Dec 03, 2025

William Blair Initiates Coverage of Viridian Therapeutics (VRDN) with Outperform Recommendation - Nasdaq

Dec 03, 2025

William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN Stock News - GuruFocus

Dec 03, 2025

William Blair Initiates Viridian Therapeutics at Outperform - marketscreener.com

Dec 03, 2025

Dec 02, 2025

Why Viridian Therapeutics Inc. (1S1) stock is favored by hedge fundsTrade Exit Summary & Detailed Earnings Play Alerts - Newser

Dec 02, 2025

Loomis Sayles & Co. L P Sells 31,884 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 02, 2025

Dec 01, 2025

Avoiding Lag: Real-Time Signals in (VRDN) Movement - news.stocktradersdaily.com

Dec 01, 2025

Geode Capital Management LLC Purchases 20,089 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 01, 2025

Nov 30, 2025

Will Viridian Therapeutics Inc. stock attract more institutional investorsTrade Exit Summary & Real-Time Volume Analysis - BỘ NỘI VỤ

Nov 30, 2025

Nov 28, 2025

Viridian Therapeutics (VRDN): Revisiting Valuation After Analyst Upgrades and Robust Revenue Growth - Sahm

Nov 28, 2025

Will Viridian Therapeutics Inc. stock continue upward momentumMarket Risk Summary & Breakout Confirmation Trade Signals - BỘ NỘI VỤ

Nov 28, 2025

Nov 25, 2025

Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail

Nov 25, 2025

Nov 24, 2025

Truist Securities Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq

Nov 24, 2025

Truist Securities Initiates Coverage on VRDN with Buy Rating | V - GuruFocus

Nov 24, 2025

Truist Securities initiates coverage on Viridian Therapeutic stock with Buy rating - Investing.com Canada

Nov 24, 2025

Why Viridian Therapeutics Shares Are Climbing Higher - TipRanks

Nov 24, 2025

Nov 22, 2025

Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues - simplywall.st

Nov 22, 2025

Nov 21, 2025